Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2021 Jun 21;30(9):1660–1668. doi: 10.1158/1055-9965.EPI-21-0162

Table 3.

Odds ratios and 95% CIs for the association between ever use of genital powder overall and by race, stratified by histotype

All cases High-grade serous All other histotypes
Ever use of body powder in genital areas Controls (%) Cases (%) MVa
OR (95% CI)b
Cases (%) MVa
OR (95% CI)b
Cases (%) MVa
OR (95% CI)b
All participants
No 5403 (68.6) 2373 (69.4) 1.00 1451 (68.8) 1.00 900 (70.2) 1.00
Yes 2478 (31.4) 1047 (30.6) 1.32 (1.17–1.48) 658 (31.2) 1.32 (1.15–1.51) 383 (29.8) 1.29 (1.10–1.52)
African Americans
No 756 (66.0) 398 (64.2) 1.00 255 (63.4) 1.00 141 (65.3) 1.00
Yes 390 (34.0) 222 (35.8) 1.22 (0.97–1.53) 147 (36.6) 1.31 (1.01–1.71) 75 (34.7) 1.05 (0.75–1.47)
Whites
No 4647 (69.0) 1975 (70.5) 1.00 1196 (70.1) 1.00 759 (71.1) 1.00
Yes 2088 (31.0) 825 (29.5) 1.36 (1.19–1.57) 511 (29.9) 1.33 (1.12–1.56) 308 (28.9) 1.38 (1.15–1.66)
a

MV=Multivariable

b

Adjusted for age (continuous), education (high school graduate/GED or less, some college, college graduate, graduate/professional school), duration of OC use (months, continuous), family history of breast cancer (no, yes), family history of ovarian cancer (no, yes), tubal ligation (yes, no), full term pregnancies (number of pregnancies ≥ 6 months, continuous), hysterectomy (no, yes), interview year (continuous), BMI (<25.0, 25.0–29.9, 30.0–34.9, ≥35.0), menopausal (premenopausal, postmenopausal), smoking (ever, never), study site (AACES, CCCS, NCOCS, LACOCS, WHI)